{"log_id": 2105025662846899922, "direction": 0, "words_result_num": 45, "words_result": [{"probability": {"variance": 0, "average": 1, "min": 1}, "location": {"width": 107, "top": 144, "height": 19, "left": 751}, "words": " czr-hkcn"}, {"probability": {"variance": 0.000117, "average": 0.99449, "min": 0.966032}, "location": {"width": 177, "top": 218, "height": 39, "left": 561}, "words": "首要综合终点组分"}, {"probability": {"variance": 0.000859, "average": 0.982917, "min": 0.924412}, "location": {"width": 52, "top": 248, "height": 22, "left": 1051}, "words": "0.206"}, {"probability": {"variance": 2.2e-05, "average": 0.993439, "min": 0.985096}, "location": {"width": 87, "top": 278, "height": 27, "left": 434}, "words": "204(4%)"}, {"probability": {"variance": 0.000188, "average": 0.992358, "min": 0.949581}, "location": {"width": 219, "top": 259, "height": 38, "left": 603}, "words": "9.2234(5%)10"}, {"probability": {"variance": 8.6e-05, "average": 0.982564, "min": 0.969487}, "location": {"width": 33, "top": 255, "height": 23, "left": 933}, "words": "11%"}, {"probability": {"variance": 4e-06, "average": 0.998582, "min": 0.99417}, "location": {"width": 133, "top": 287, "height": 37, "left": 174}, "words": "心血管死亡率"}, {"probability": {"variance": 0.000192, "average": 0.990707, "min": 0.951103}, "location": {"width": 214, "top": 300, "height": 40, "left": 610}, "words": "0.8309(7%)14"}, {"probability": {"variance": 0.029743, "average": 0.860143, "min": 0.616928}, "location": {"width": 23, "top": 298, "height": 22, "left": 942}, "words": "259"}, {"probability": {"variance": 3e-06, "average": 0.998476, "min": 0.995387}, "location": {"width": 54, "top": 292, "height": 19, "left": 1055}, "words": "0.001"}, {"probability": {"variance": 0, "average": 0.999261, "min": 0.998689}, "location": {"width": 44, "top": 337, "height": 23, "left": 178}, "words": "中风"}, {"probability": {"variance": 7.4e-05, "average": 0.995284, "min": 0.976078}, "location": {"width": 78, "top": 320, "height": 27, "left": 438}, "words": "232(5%"}, {"probability": {"variance": 2e-06, "average": 0.998481, "min": 0.995794}, "location": {"width": 56, "top": 335, "height": 21, "left": 1057}, "words": "0.491"}, {"probability": {"variance": 1.8e-05, "average": 0.993182, "min": 0.987369}, "location": {"width": 69, "top": 364, "height": 26, "left": 447}, "words": "98(4%"}, {"probability": {"variance": 0.000368, "average": 0.988338, "min": 0.934742}, "location": {"width": 158, "top": 348, "height": 32, "left": 609}, "words": "92188(4%)"}, {"probability": {"variance": 2e-06, "average": 0.997278, "min": 0.995908}, "location": {"width": 24, "top": 341, "height": 22, "left": 945}, "words": "7%"}, {"probability": {"variance": 1e-06, "average": 0.999225, "min": 0.997439}, "location": {"width": 85, "top": 376, "height": 28, "left": 180}, "words": "心肌梗死"}, {"probability": {"variance": 0.009619, "average": 0.966912, "min": 0.656863}, "location": {"width": 204, "top": 454, "height": 39, "left": 189}, "words": "每1000患者-年随访"}, {"probability": {"variance": 0.003491, "average": 0.984411, "min": 0.693092}, "location": {"width": 542, "top": 474, "height": 60, "left": 201}, "words": "对基线时弗明翰危险因素评分及心电图LVH程度进行校正"}, {"probability": {"variance": 0.000322, "average": 0.993292, "min": 0.911693}, "location": {"width": 844, "top": 541, "height": 74, "left": 227}, "words": "LFE研究的其它临床终点:总死亡率、需要住院治疗的心衰或心绞痛,冠脉或周围血管"}, {"probability": {"variance": 3.4e-05, "average": 0.997706, "min": 0.968392}, "location": {"width": 887, "top": 583, "height": 75, "left": 186}, "words": "重建手术和心脏骤停复苏。两个治疗组在降低这些临床终点发生率方面没有显著差别。与阿替"}, {"probability": {"variance": 0.000895, "average": 0.991253, "min": 0.845609}, "location": {"width": 520, "top": 643, "height": 57, "left": 187}, "words": "洛尔组相比,氯沙坦组患者LVH的心电图指标显著降低"}, {"probability": {"variance": 8.4e-05, "average": 0.995291, "min": 0.957883}, "location": {"width": 845, "top": 666, "height": 72, "left": 232}, "words": "在基线时有糖尿病史(n=1195)或单纯收缩期高血压(ISH)史(n=1326)的亚组患者"}, {"probability": {"variance": 3e-06, "average": 0.998988, "min": 0.989705}, "location": {"width": 886, "top": 706, "height": 76, "left": 193}, "words": "中,以阿替洛尔作为对照,评价氯沙坦对心血管患病率和死亡率的影响。在降低首要综合临床"}, {"probability": {"variance": 5e-06, "average": 0.998724, "min": 0.989417}, "location": {"width": 887, "top": 747, "height": 75, "left": 194}, "words": "终点方面,在亚组人群中得到的结果与氯沙坦在整个研究人群中的治疗益处一致:观察到糖尿"}, {"probability": {"variance": 7.6e-05, "average": 0.996795, "min": 0.941167}, "location": {"width": 889, "top": 788, "height": 77, "left": 194}, "words": "病患者首要综合终点的危险性降低24%(p=0.03),而对于单纯性收缩期高血压患者,危险性降"}, {"probability": {"variance": 0.001192, "average": 0.989655, "min": 0.827792}, "location": {"width": 889, "top": 831, "height": 74, "left": 197}, "words": "低25%(p=0.06)。与在整个研究人群中得到的结果一致,降低中风的危险性对于糖尿病患者或"}, {"probability": {"variance": 1e-06, "average": 0.99893, "min": 0.996709}, "location": {"width": 414, "top": 896, "height": 50, "left": 199}, "words": "单纯性收缩期高血压患者有重要的临床益处"}, {"probability": {"variance": 2e-06, "average": 0.998971, "min": 0.995255}, "location": {"width": 843, "top": 913, "height": 72, "left": 245}, "words": "在这个研究中,氯沙坦能很好耐受,由于不良反应中断试验的发生率显著较低,其耐受性"}, {"probability": {"variance": 7e-06, "average": 0.997488, "min": 0.992329}, "location": {"width": 130, "top": 996, "height": 30, "left": 205}, "words": "优于阿替洛尔"}, {"probability": {"variance": 4.8e-05, "average": 0.993964, "min": 0.980484}, "location": {"width": 113, "top": 1077, "height": 36, "left": 210}, "words": "ENAL研究"}, {"probability": {"variance": 5e-06, "average": 0.99888, "min": 0.989605}, "location": {"width": 847, "top": 1120, "height": 70, "left": 252}, "words": "氯沙坦肾脏保护研究( RENAAL研究)是一项大型、多中心、随机、安慰剂对照、双盲临"}, {"probability": {"variance": 5.3e-05, "average": 0.996061, "min": 0.958892}, "location": {"width": 866, "top": 1161, "height": 74, "left": 211}, "words": "床研究,全球入组1513位2型糖尿病伴蛋白尿患者(其中751位用氯沙坦治疗),有或无"}, {"probability": {"variance": 0.01647, "average": 0.968784, "min": 0.401681}, "location": {"width": 887, "top": 1207, "height": 69, "left": 214}, "words": "血压病史。研究目的是确定氯沙坦在降血压和超越降血压的益处方面的肾保护作用取得"}, {"probability": {"variance": 0.019301, "average": 0.951301, "min": 0.377462}, "location": {"width": 947, "top": 1222, "height": 107, "left": 214}, "words": "这个目标,实验设计为两个治疗组均达到相同的血压控制在常规抗高血压疗法制剂"}, {"probability": {"variance": 0.002432, "average": 0.980328, "min": 0.795611}, "location": {"width": 888, "top": 1286, "height": 73, "left": 218}, "words": "和血管紧张素II受体拮抗剂除外)的基础之上,有蛋白尿,血清肌酐为1.3-3.0mg/d的患"}, {"probability": {"variance": 1.2e-05, "average": 0.998053, "min": 0.98408}, "location": {"width": 865, "top": 1328, "height": 73, "left": 219}, "words": "者被随机分配到氯沙坦50mg组,每天一次,根据降压效果可调整氯沙坦剂量,或安慰剂组"}, {"probability": {"variance": 7e-06, "average": 0.998775, "min": 0.984081}, "location": {"width": 886, "top": 1370, "height": 71, "left": 221}, "words": "适当时,指导研究者调整研究药物剂量至100mg,每天一次;72%的患者在大部分研究时间内"}, {"probability": {"variance": 0.000207, "average": 0.995808, "min": 0.905897}, "location": {"width": 890, "top": 1410, "height": 73, "left": 223}, "words": "服用氯沙坦的剂量是100mg,每日一次。根据需要,两个研究组均可添加其它抗高血压药利"}, {"probability": {"variance": 0, "average": 0.98495, "min": 0.98495}, "location": {"width": 91, "top": 1427, "height": 58, "left": 994}, "words": " PHARM"}, {"probability": {"variance": 0.004604, "average": 0.923752, "min": 0.8559}, "location": {"width": 17, "top": 1440, "height": 24, "left": 1077}, "words": "LA"}, {"probability": {"variance": 0, "average": 0.795627, "min": 0.795627}, "location": {"width": 39, "top": 1446, "height": 34, "left": 1094}, "words": " CE"}, {"probability": {"variance": 1.6e-05, "average": 0.996059, "min": 0.98864}, "location": {"width": 167, "top": 1502, "height": 42, "left": 1005}, "words": "杭州默沙东"}, {"probability": {"variance": 0.034947, "average": 0.899607, "min": 0.460639}, "location": {"width": 173, "top": 1546, "height": 40, "left": 1001}, "words": "制药有限公司8"}, {"probability": {"variance": 0, "average": 0.73903, "min": 0.73903}, "location": {"width": 79, "top": 1632, "height": 29, "left": 1061}, "words": "头"}], "language": 3}